

Financial Tear Sheet

Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

Primary IR Contact

Stern Investor Relations, Inc.

Sarah McCabe

Phone: 212-362-1200

E-mail:

sarah@sternir.com

Stock Performance

IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$11.20**

Change (%) **▲ 0.51 (4.77%)**

Volume 2,064,590

52 Week High \$19.90

52 Week Low \$6.60

Market Cap \$1,021,880,287

Rolling EPS -1.35

PE Ratio 0

Shares Outstanding 95,592,169

Data as of October 16, 2018 4:00 p.m. ET



Recent Headlines

October 12, 2018

[Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately \\$220 Million of Common Stock](#)

October 11, 2018

[Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock](#)

October 11, 2018

[Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company's Clinical Program](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
October 12, 2018	8-K
October 12, 2018	424B5
October 11, 2018	S-3MEF
October 11, 2018	424B5

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.